AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
Now that AnGes MG has scored its targeted number of trial cases, it will analyze the results and complete the trial for each case as soon as the case's evaluation period expires.
In Japan, AnGes MG is currently proceeding with phase III clinical trials of HGF gene medicine intended for the treatment of peripheral arterial disease.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Nov 25, 2005|
|Previous Article:||A&T to Acquire Infectious Disease Control Business from Nagase.|
|Next Article:||Kawasaki Kisen Kaisha Establishes Logistics Center in Washington State.|